Clinical Trial Update: Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating Erlotinib with sequential PET in advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Lung Cancer Group Cologne | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN